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ABSTRACT 
Obesity, the disease of the twenty-first century, has 
a range of serious consequences to health. These are 
related in part to abnormal glucose levels, resulting 
in inflammatory and atherogenic response, 
hypertension and abnormal lipid profile. This 
increases the risk of cardiovascular disease 
significantly besides developing diabetes later. 
Hyperglycaemia is diagnosed with impaired fasting 
glucose and/or impaired glucose tolerance or 
elevated glycated haemoglobin (HbA1c). The Royal 
Australian College of General Practitioners (RACGP) 
guidelines for diagnosis using oral glucose tolerance 
test (or HbA1c) recognise the importance of 
extending diagnosis beyond simply identifying 
diabetes. This is relevant in view of the risk of 
composite cardiovascular events, coronary heart 
disease, stroke, and all-cause mortality associated 
with abnormal blood glucose. Since the pilot 
population mirrors this morbidity, the aviation 
regulator has an obligation to consider the impact in 
terms of aviation safety. Furthermore, although 
primary care literature predominantly focusses on 
the importance of diagnosing diabetes, from a 
regulator’s perspective there are incapacitation risks 
originating outside that narrow diagnosis. They arise 
once the control of glucose has begun to deteriorate. 
This article considers the regulatory importance of 
pilots and controllers who present with 
hyperglycaemia, or what is sometimes termed  
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“prediabetes”. This includes the evidence for the risk 
assessment to help minimise the likelihood of an 
adverse event due to atherosclerotic cardiovascular 
disease among those holding aviation medical 
certificates, in turn promoting aviation safety.    
The impact of hyperglycaemia is not trivial and 
should not be minimised. To quote: “By the time a 
typical obese middle-aged subject is diagnosed with 
type 2 diabetes, he has already accrued significant 
cardiovascular risk in terms of hypertension, 
endothelial dysfunction, coagulopathy, atherogenic 
lipid profile and circulating pro-inflammatory 
adipocytokines” [1]. The endothelial dysfunction and 
inflammatory response, aggravated by stress 
responses, lead to vascular injury and associated 
plaque formation. Such atherosclerotic lesion is 
susceptible to “sudden expansion from acute 
thrombus formation, forming a nidus for platelet 
thrombosis, haemorrhage of atherosclerotic plaque 
microvessels, and rupture of the fibrous cap” [2]. It is 
known that about twenty per cent of newly 
diagnosed diabetics already have evidence of 
cardiovascular disease (CVD) [1]. “In other words, the 
ticking clock for vascular disease begins well before 
diagnosis of diabetes” [3].  
The challenge therefore rests in making the 
diagnosis. It is known that the population with 
prediabetes remains asymptomatic during a 
prolonged phase before type 2 diabetes manifests. 
Prediabetics demonstrate an atherogenic pattern of 
risk factors several years prior to diagnosed 
diabetes, “possibly caused by obesity, 
hyperglycaemia, and especially hyperinsulinemia” 
[4]. Such vascular damage is preventable, hence 
needs to be identified and monitored. Prediabetes is 
the term used for individuals with impaired fasting 
glucose (IFG) and/or impaired glucose tolerance 





(HbA1c) [7, 8], indicating the relatively high risk for 
the future development of diabetes. Such 
intermediate hyperglycaemic states have An 
incidence of diabetes of 6% per year compared with 
0.5% for normoglycaemics, and an absolute 
incidence of diabetes of 78 per 1000 person-years 
[9]. This means that during the next three to eight 
years, 30% to 40% of pre-diabetics will be diagnosed 
as type 2 diabetes [10]. Measurement of fasting 
blood glucose or HbA1c is an acceptable, reliable and 
relatively cheap method of identifying this 'prolonged 
preclinical phase' [11]. Such a screening test is 
directly relevant to the disease process and our 
understanding of the pathophysiology of 
hyperglycaemia. There are also proven benefits from 
intervention strategies which delay or prevent the 
disease [12], which will be all the more relevant with 
the rising levels of obesity, diabetes and CVD among 
the Australian population [13, 14]. Dunstan et al. in 
their landmark AusDiab study proposed that those 
overweight be screened for prediabetes and diabetes 
using a stepped approach of fasting plasma glucose 
measurement followed by a 75g oral glucose 
tolerance test [15]. This is also the recommended 
practice by the Royal Australian College of General 
Practitioners (RACGP) where equivocal values of 
fasting (5.5-6.9 mmol/L) or random blood glucose 
(5.5-11 mmol/L) warrant an oral glucose tolerance 
test (OGTT) [16]. Such an approach recognises the 
importance of extending diagnosis beyond simply 
identifying diabetes.  
Pilots and air traffic controllers are likely to be at 
similar risk of CVD and diabetes as the population 
pool they come from. Hence the aviation regulators, 
including the Civil Aviation Safety Authority (CASA), 
have risk assessment protocols which go beyond 
diagnosing hyperglycaemia in isolation, and include 
risk assessment for CVD. For example, the CASA 
timetable for periodic medical examination requires 
estimation of fasting blood glucose and if this is 5.5 
mmol/L or above, an OGTT [17]. This enables the 
diagnosis prediabetes or diabetes to be made, and 
thus informs the risk estimation for CVD.  
The rationale behind CASA’s clinical practice 
guidelines for initial assessment of hyperglycaemia, 
with focus on cardiovascular morbidity is reviewed in 
this article [18].  
HYPERGLYCAEMIA – IFG AND IGT - AND THE 
BURDEN OF MORBIDITY 
As a regulator, following an expert guideline 
becomes problematic when there is divergence of 
guidance. Concerning prediabetes, there are five 
different definitions. The World Health Organisation 




mmol/L and IGT as 2-hour plasma glucose between 
7.8 to 11.0 mmol/L after 75g glucose load [5]. The 
American Diabetes Association (ADA) defines 
prediabetes as raised glycated haemoglobin (HbA1c) 
of 5.7 to 6.4% (39-47 mmol/mol) [7] while an 
International Expert Committee (IEC) criterion is 
elevated HbA1c of 6.0-6.4% (42-47 mmol/mol) [8]. In 
the absence of consensus on the definition, the 
prevalence of prediabetes will inevitably vary 
between different definitions [19]. Thus, it is 
important to understand that since these definitions 
have “different sensitivities, specificities, and 
morbidity and mortality hazard ratios”, “the choice of 
which test and threshold to use to identify people 
with intermediate hyperglycaemia will depend on the 
specific needs and goals of the screening 
programme.” [20]. CASA follows the RACGP 
guidelines for screening for prediabetes or diabetes 
[11]. 
WHAT MATTERS MOST – IGT OR IFG? 
The AusDiab study had shown an approximately 30 
percent and 20 percent increased risk of 
cardiovascular mortality with one standard deviation 
increase in fasting and 2-hour plasma glucose 
values, respectively [21, 22]. The DECODE study 
found a strong association between 2-hour glucose 
with mortality due to CVD than fasting glucose 
concentration [23]. Tominaga et al. reported that 
unlike IGT, IFG is not considered an independent risk 
factor for CVD [24]. Some meta-analyses have 
reported conflicting associations whether IFG or IGT 
was more strongly associated with CVD [25, 26]. The 
pathophysiological difference between IFG and IGT 
is that while the former reflects reduced hepatic 
insulin sensitivity, impaired first-phase insulin 
secretion, and normal/near-normal muscle insulin 
sensitivity, the latter has nearly normal hepatic 
insulin sensitivity and marked reduced peripheral 
insulin sensitivity combined with defective late 
insulin secretion [27, 28, 29]. 
Santaguida et al. summarised that hyperglycaemia, 
reflected by IFG or IGT, is a risk factor for fatal and 
nonfatal CVD (Table 1). They reported that IGT is a 
greater risk factor for CVD than IFG since the former 
is a physiological stress response to non-
physiological glucose loading, in turn “exposing a 
degree of metabolic dysregulation that would not be 
apparent on the basis of fasting glucose levels 
alone” [30].   
 
 
Table 1: Risk estimates for cardiovascular disease 
among those with abnormal glucose tolerance test 
(Modified from Santaguida et. al. [30]) 
 
 Impaired Fasting 
Glucose (IFG) 
(95% CI* in 
parentheses) 
Impaired Glucose 
Tolerance (IGT)    
(95% CI in 
parentheses) 
a. Risk for non-fatal CVD outcome 
(i) Annualised 
risk estimates for 
any nonfatal CVD 
event 




1.24 (1.08 – 1.43) 
to  
1.41 (1.17 – 1.69) 
2.43 (1.44 – 4.10) 
to  
2.46 (1.46 – 4.12) 
(iii) Attributable 
risk in the 
exposed group 
0% - 32.9% 52.8% - 52.9% 
b. Risk for fatal CVD outcome 
(i) Annualised 
risk per 100 
persons in the 
exposed groups 
01.10 – 1.54 0.06 – 0.76 
(ii)  Unadjusted 
annualised 
relative risk 
1.32 (1.04 – 1.72)  1.67 (1.23 – 2.26) 
to 
3.08 (1.47 – 6.47) 
(iii) Attributable 
risk in the 
exposed group. 
11.8% - 39.5% 24.8% - 67.3% 
c. Risk for mortality  
(i) Annualised 
risk per 100 
persons in the 
exposed groups 
0.56 – 1.39 0.09 – 2.44 
(ii)  Unadjusted 
annualised 
relative risk 
1.18 (1.03 – 1.35) 
to 1.45 (1.27 – 
1.66) 
1.36 (1.12 – 1.66) 
to  
3.18 (1.79 – 5.63) 
(iii) Attributable 
risk in the 
exposed group 
13.9% - 61.2% 0% - 67.2% 
* CI = Confidence Interval 
The risk of composite cardiovascular events, 
coronary heart disease, stroke, and all-cause 
mortality increases with IFG or IGT [31]. Abdul-Ghani 
et al. surmised that “IGT was an independent risk 
predictor for cardiovascular morbidity and mortality 
and for total mortality”. They reported that “the 
multivariate adjusted HR (95% CI) was 1.49 (0.95–
2.34) for CHD (coronary heart disease) incidence, 
2.34 (1.42–3.85) for CVD mortality, and 1.65 (1.13–
2.40) for all-cause mortality”. This was not 
confounded by the subsequent development of overt  
 
diabetes” [27]. Hence 2-hour glucose value has 
strong association with insulin resistance, in turn 
having an independent effect on cardiovascular risk 
[32]. 
An indicator of glucose tolerance usually not taken 
into consideration is the one-hour post load 
glycaemia value of an oral glucose tolerance test. 
This value depends on the insulin sensitivity in 
skeletal muscles and beta-cell function. One-hour 
post load recorded glycaemia values of more than 
8.6 mmol/L have 16.7% incidence rate of type 2 
diabetes over five years [33] and have strong 
association with predictors for future adverse 
cardiovascular events [21]. Though it may help 
identify those more susceptible to atherosclerotic 
changes, it is not yet an acceptable diagnostic 
measure for prediabetes.  
Another possible indicator, HbA1c, offers average 
levels of blood glucose over past three months, with 
higher reproducibility than fasting values. But HbA1c 
values between 5.7% and 6.4% (39-46 mmol/mol) 
have lower sensitivity to identify prediabetics as 
compared with IFG and IGT [34, 35]. HbA1c has low 
concordance with IFG and IGT to diagnose 
prediabetes. Possible explanation of this 
discordance is that factors affecting glycation rate, 
such as oxidative stress, determine the HbA1c 
values [36]. Increased body weight is associated with 
increased oxidative stress, as are reportedly higher 
HbA1c values found among obese. Hence HbA1c 
among obese may be higher instead of the true 
concentration of the blood glucose [10]. There is 
marginal difference in optimal HbA1c cut-off points 
for different age groups, with young and middle-aged 
at 5.6% (38 mmol/mol) compared with 5.7% (39 
mmol/mol) for the elderly [10, 37]. A prospective 
study over a decade did not find increase in all-cause 
mortality among those with HbA1c levels in the 
prediabetic range [38]. Thus, CASA does not 
recommend HbA1c for diagnosis of prediabetes [18].  
In summary, all indicators of hyperglycaemia reflect 
increase event rates for cardiovascular disease. It is 
appropriate therefore that these factors are included 
in aviation risk assessment.  
IMPLICATIONS FOR AVIATION MEDICAL 
CERTIFICATE HOLDERS – AIM AT MINIMISING 
THE LOSS OF TRAINED MANPOWER  
Recent data suggests that 63% Australians are 
overweight or obese, with rising trend from 39% of 
people aged 18–24 to 74% for those aged 65–74 
[13]. The AusDiab study found that 17.4% of men and 
15.4% of women had either IGT or IFG. There is 5.8% 
and 10.6% prevalence of IFG and IGT, respectively, 
with former being more prevalent in men (8.1% v 3.4% 
in women) and latter among women (11.9% v 9.2% in 
men) [15].  
 
CVD is the leading cause of ill-health among 
Australians [13]: (a) coronary heart disease at 13% 
was the leading cause of death in 2013; (b) coronary 
heart disease, at 10% of deaths among those below 
75 years of age, was the leading cause of premature 
death in 2011–2013; and (c) an estimated 3.6% 
adults had been diagnosed with coronary heart 
disease in 2014–15. Elsewhere, Valenti et al. in a 
prospective study among asymptomatic individuals 
without known coronary heart disease and coronary 
artery calcium score of 0 at baseline found an 
increased risk of mortality among diabetics (Hazard 
Ratio 2.53, 95% CI 1.74-3.69) after nearly 15 years of 
follow up [39].  Evidently atherosclerosis is the 
precipitating factor in cardiovascular disease, with 
obesity and hyperglycaemia being the commonest 
risk factors. Thus, it is not difficult to discern the 
likely implications for increasing morbidity pattern 
among pilots and air traffic controllers, who are from 
the same population pool. 
Australian applicants for class 1 and 3 medical 
certificates undergo special periodic examination, 
including test for blood glucose [17]. CASA’s decision 
matrix for the investigation of abnormal glucose and 
raised BMI, follows RACGP guidelines [16, 18, 40, 41]. 
Conceptually, it is also consistent with International 
Civil Aviation Organisation (ICAO) [42] guidelines. 





















Table 2: Risk Assessment Criteria for Abnormal 
Glucose Metabolism as followed by CASA and other 
jurisdictions 
 
Once prediabetes is diagnosed among the aviation 
medical certificate holders, CASA recommends that 
the subsequent follow up is by undertaking a blood 
test for HbA1c, as recommended by RACGP [40]. 
This permits ongoing screening for diabetes and 
calculation of CVD risk [17, 18].   
WHERE TO NEXT? 
Recent work by the Auckland group has 
demonstrated the validity of a multifactorial risk tool 
for cardiovascular risk assessment [43]. This 
includes HbA1c levels and will provide risk 
assessments for diabetics and pre-diabetics, as well 
as those with declared cardiovascular disease, e.g. 
post myocardial infarction. It is likely that the data 
from this study will impact the practicalities of 
considering this particular risk, and process changes 
will be needed. 
It is important to distinguish aeromedical decision 
making from clinical management of diseases and 
disabilities, such as those individuals with pre-
diabetes or diabetes. In the course of a risk 
assessment, the identification of a medical problem 
is followed by a referral to the relevant 
treatingdoctor. As with other regulatory authorities, 
CASA relies upon the relevant regulations to define  
Aviation 
Authority 
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the acceptable level of risk. This is also in line with 
ICAO’s amendment 173 to Annex 1 (health promotion 
amendment – standard 1.2.4.3) as extracted below:  
1.2.4.3 The Licensing Authority shall implement 
appropriate aviation-related health promotion for 
licence holders subject to a Medical Assessment to 
reduce future medical risks to flight safety. 
Note 1.— Standard 1.2.4.2 indicates how appropriate 
topics for health promotion activities may be 
determined. 
Note 2.— Guidance on the subject is contained in 
the Manual of Civil Aviation Medicine (Doc 8984). 
Note 3.— Guidance on the relationship between the 
Licensing Authority and the implementation of 
Medical Assessment for licence holders is contained 
in the Manual of Procedures for Establishment and 
Management of a State’s Personnel Licensing 
System (Doc 9379). 
CONCLUSION 
CASA’s assessment protocol evaluates the risk of 
abnormal glucose metabolism, which is associated 
with a markedly higher morbidity and mortality due 
to CVD. Besides the clinical imperatives to “reduce 
premature death, improve quality of life, and lessen 
individual and economic burdens of associated 
morbidities, decreased work productivity, and high 
cost of medical care” [2], this promotes aviation 
safety by evidence based risk assessment to 
minimise the likelihood of functional incapacity or in-
flight incapacitation among those holding aviation 
medical certificates due to atherosclerotic CVD.   
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